Biomarker Signatures Predict Aging Health Quality
|
By LabMedica International staff writers Posted on 17 Jan 2017 |
A panel of 19 biomarkers in the blood was utilized to create molecular signatures that are able to predict how well an individual is aging and how severe the likelihood that he or she will develop an aging-related disease.
To establish these signatures, investigators at Boston University measured 19 blood biomarkers that included constituents of standard hematological measures, lipid biomarkers, and markers of inflammation and frailty in 4704 participants of the Long Life Family Study (LLFS). The biomarkers were selected based upon their noted quantitative change with age and specificity for inflammatory, hematological, metabolic, hormonal, or kidney functions.
The LLFS is a family-based study that enrolled 4935 participants including subjects and siblings (30%), their offspring (50%), and spouses (20%), with ages between 30 and 110 years. Approximately 40% of enrolled participants were born before 1935 and had a median age at enrollment of 90 years and 45% participants were male. Almost 55% of participants from the subject generation (birth year prior to 1935) have died since enrollment, with a median age at death of 96 years. Mortality in the generation born after 1935 is lower (3%) and among these few that have died, median age at death is currently 69 years.
The investigators used an agglomerative algorithm to analyze distribution of the 19 biomarkers and then grouped LLFS participants into clusters that yielded 26 different biomarker signatures.
To test whether these signatures were associated with differences in biological aging, the investigators correlated them with longitudinal changes in physiological functions and incident risk of cancer, cardiovascular disease, type II diabetes, and mortality using longitudinal data collected in the LLFS. One signature was found to be associated with significantly lower mortality, morbidity, and better physical function relative to the most common biomarker signature in LLFS, while nine other signatures were associated with less successful aging, characterized by higher risks for frailty, morbidity, and mortality.
"Many prediction and risk scores already exist for predicting specific diseases like heart disease," said first author Dr. Paola Sebastiani, professor of biostatistics at Boston University. "Here, though, we are taking another step by showing that particular patterns of groups of biomarkers can indicate how well a person is aging and his or her risk for specific age-related syndromes and diseases. These signatures depict differences in how people age, and they show promise in predicting healthy aging, changes in cognitive and physical function, survival, and age-related diseases like heart disease, stroke, type II diabetes, and cancer."
The study was published in the January 6, 2017, online edition of the journal Aging Cell.
To establish these signatures, investigators at Boston University measured 19 blood biomarkers that included constituents of standard hematological measures, lipid biomarkers, and markers of inflammation and frailty in 4704 participants of the Long Life Family Study (LLFS). The biomarkers were selected based upon their noted quantitative change with age and specificity for inflammatory, hematological, metabolic, hormonal, or kidney functions.
The LLFS is a family-based study that enrolled 4935 participants including subjects and siblings (30%), their offspring (50%), and spouses (20%), with ages between 30 and 110 years. Approximately 40% of enrolled participants were born before 1935 and had a median age at enrollment of 90 years and 45% participants were male. Almost 55% of participants from the subject generation (birth year prior to 1935) have died since enrollment, with a median age at death of 96 years. Mortality in the generation born after 1935 is lower (3%) and among these few that have died, median age at death is currently 69 years.
The investigators used an agglomerative algorithm to analyze distribution of the 19 biomarkers and then grouped LLFS participants into clusters that yielded 26 different biomarker signatures.
To test whether these signatures were associated with differences in biological aging, the investigators correlated them with longitudinal changes in physiological functions and incident risk of cancer, cardiovascular disease, type II diabetes, and mortality using longitudinal data collected in the LLFS. One signature was found to be associated with significantly lower mortality, morbidity, and better physical function relative to the most common biomarker signature in LLFS, while nine other signatures were associated with less successful aging, characterized by higher risks for frailty, morbidity, and mortality.
"Many prediction and risk scores already exist for predicting specific diseases like heart disease," said first author Dr. Paola Sebastiani, professor of biostatistics at Boston University. "Here, though, we are taking another step by showing that particular patterns of groups of biomarkers can indicate how well a person is aging and his or her risk for specific age-related syndromes and diseases. These signatures depict differences in how people age, and they show promise in predicting healthy aging, changes in cognitive and physical function, survival, and age-related diseases like heart disease, stroke, type II diabetes, and cancer."
The study was published in the January 6, 2017, online edition of the journal Aging Cell.
Latest Molecular Diagnostics News
- DPYD Genotyping Assay Supports Safer Fluoropyrimidine Chemotherapy Dosing
- Project to Develop Maternal Blood Test for Rapid Fetal Oxygen Deprivation Detection
- WHO Emergency Listing Supports Rapid Molecular Testing for Ebola Outbreak Response
- FDA Clears Liquid Biopsy Test to Guide Earlier Breast Cancer Therapy Switch
- Automated System Streamlines DNA Recovery for MRD-Sensitive Testing
- New Liquid Biopsy Platform Uses Red Blood Cells to Detect Hidden Cancer Signals
- Urine Genomic Test Detects More Than Nine in Ten Suspected Bladder Cancers
- Liquid Biopsy Test Predicts Tissue of Origin in Cancer of Unknown Primary
- Study Identifies Genetic Marker Missing from Common Pharmacogenomic Panels
- Single-Tube CRISPR Test Detects Pathogens and Genetic Variants in 30 Minutes
- New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients
- New Automation Platform Standardizes DNA and RNA Extraction Across Clinical Workflows
- Single Genetic Analysis Identifies Causes of Premature Ovarian Insufficiency
- New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
- Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
- Self-Collected HPV Testing Reaches Patients Missed by Routine Screening
Channels
Clinical Chemistry
view channel
Blood Biomarker May Track Bone Metastases in Medullary Thyroid Cancer
Medullary thyroid cancer (MTC) is a rare malignancy that often progresses silently, frequently going undetected until it reaches advanced stages. By the time it spreads to bone, it can produce unusual... Read more
Blood Biomarkers Help Assess Growth Risks During Steroid Treatment in Duchenne Muscular Dystrophy
Children with Duchenne muscular dystrophy (DMD) commonly receive long-term corticosteroids to slow disease progression, but these drugs can impair linear growth and weaken bone. Understanding how specific... Read moreHematology
view channel
Borderline Anemia May Carry Higher Risk Than Current Thresholds Suggest
Hemoglobin concentration is among the most frequently ordered blood tests in primary and hospital care. In older adults, both high and low values have been linked to adverse outcomes, including cognitive... Read more
Biomarker-Guided Framework Aims to Guide Mantle Cell Lymphoma Therapy
Mantle cell lymphoma can follow widely variable courses, from indolent disease to rapidly progressive cancer, complicating initial treatment selection. Many therapeutic decisions still rely on patient... Read moreImmunology
view channel
New Cellular Map May Help Predict Crohn’s Disease Course in Children
Crohn’s disease in children is a common and debilitating form of inflammatory bowel disease, marked by chronic intestinal inflammation and limited pediatric-specific treatments. Clinicians must decide... Read more
Temporal Immune Profiling Reveals How Sepsis States Change Over Time
Sepsis is a life-threatening condition in which the immune response to infection becomes dysregulated, leading to rapid organ failure and death. Although antimicrobials and organ support remain standard... Read more
Study Identifies Immune Cells That Drive Harmful Autoantibody Responses in COVID-19
Autoantibodies that mistakenly attack the body’s own tissues have been linked to severe COVID-19, Long COVID, and increased risk of autoimmune disease. However, the origins of these autoantibodies during... Read moreMicrobiology
view channel
Research Strengthens Bundibugyo Virus Outbreak Readiness with Faster Diagnostics
Bundibugyo virus (BDBV), a species of ebolavirus, causes severe hemorrhagic disease and can be difficult to diagnose rapidly during outbreaks. Recent regulatory changes have further complicated swift deployment... Read more
Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification
Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. Clinicians therefore need tools that improve risk stratification... Read morePathology
view channel
FDA Clearance Expands Digital Pathology Options for Clinical Laboratories
Hamamatsu Photonics K.K. (Hamamatsu, Japan) announced it received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the NanoZoomer S20MD and NanoZoomer S540MD slide scanner systems.... Read more
Label-Free Imaging Reveals Hidden Immune Activity in Blood Samples
Peripheral blood mononuclear cells (PBMCs) are widely used to monitor infection, autoimmunity, cancer, and treatment response, yet most assays depend on fluorescent labels that can perturb cells and provide... Read moreTechnology
view channel
New Multipurpose Centrifuge Combines High Capacity with Sustainable Cooling
Laboratories often need centrifugation that accommodates multiple vessel formats while maintaining controlled temperatures to protect sensitive samples. Intuitive controls and repeatable operation can... Read more
Bacterial Vesicle Expression System Streamlines Production of Cancer Diagnostic Proteins
Recombinant proteins are central to many cancer diagnostics and therapies, but numerous targets remain difficult and costly to produce because they are unstable, toxic to microbial hosts, or require precise folding.... Read moreIndustry
view channel
New NHS Partnership Expands Access to Epigenetic CNS Tumor Classifiers
Rapid and accurate classification of central nervous system tumors remains a challenge, particularly in children where histology alone can misclassify aggressiveness and drive overtreatment.... Read more







